Skin immune biomarker predicts the development of AD in the pediatric population 

With a prevalence of 15-20%, atopic dermatitis (AD) is the most common skin disease in the pediatric population. At EADV 2022, The Barrier dysfunction in Atopic newBorns (BABY) study is ready to present results suggesting an essential role of immune biomarkers in predicting the development of AD during the first two years of life.